ArticleScientific reports2025
Diversity of oxidative stress and senescence phenotypes induced by chemotherapeutic agents in HUVECs.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Replicative and Air Pollution-Induced Senescence: Telomere Dysfunction, Mitochondrial Stress, and Modulatory Effects of Astragaloside IV in Endothelial and Vascular Smooth Muscle Cells.Cardiovascular toxicology · 2026Article
- Senolytics Reverse PMCardiovascular toxicology · 2026Article
- Optimizing Primary Human Salivary Stem/Progenitor Cells for Tissue Engineering Applications.bioRxiv : the preprint server for biology · 2026Article
- Mitochondrial dysfunction in endothelial senescence: implications for vascular remodeling and therapeutic strategies.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced endothelial cell senescence impacts tumor angiogenesis and therapy outcomes. While senescence can suppress tumorigenesis, it may also promote chronic inflammation and vascular toxicity. This study investigates how different chemotherapeutic agents induce senescence in human umbilical vein endothelial cells (HUVECs) and explores the roles of reactive oxygen species (ROS) and ataxia telangiectasia mutated (ATM) kinase. HUVECs were treated with DNA crosslinkers (doxorubicin, mitomycin C), topoisomerase inhibitors (etoposide, camptothecin), and methotrexate (MTX). Senescence was assessed via senescence-associated β-galactosidase (SA-β-gal) staining, senescence-associated secretory phenotype related factors, Phalloidin staining, immunofluorescence (p53, Ki67, 53BP1, γH2AX), mitochondrial morphology, ROS measurement, and transcriptomic sequencing. ROS scavenger Mito-Q and ATM inhibitor KU55933 were co-administered to evaluate their modulatory effects. SA-β-gal staining demonstrated that all agents induced senescence, with etoposide being the most potent (80% SA-β-gal-positive cells) and methotrexate the weakest (40%). DNA damage markers (53BP1, γH2AX) and ROS levels increased significantly, accompanied by mitochondrial fragmentation, reduced Ki67, and increased cell morphology. Furthermore, Mito-Q alleviated methotrexate-induced senescence but had no effect on other agents. ATM inhibition did not demonstrate an effect across all treatments in this study. Transcriptomic analysis revealed the p53 signaling pathway as a pivotal molecular determinant in chemotherapy-induced cellular senescence. MTX appeared mechanistically linked to TNF-mediated signaling cascades. Chemotherapeutic agents triggered endothelial senescence via DNA damage and ROS accumulation, with heterogeneity in potency and mechanisms. ROS scavengers may mitigate methotrexate-associated vascular toxicity, and targeting ROS could enhance chemotherapy safety by preserving endothelial function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.